Neuroendocrine peritoneal disease and [Lu]DOTATATE peptide receptor radionuclide therapy: a therapeutic challenge with potential clinical complications.

Date publication

avril 2025

Journal

European journal of nuclear medicine and molecular imaging

Auteurs

Membres identifiés du Cancéropôle Est :
Pr IMPERIALE Alessio , Dr BALTZINGER Philippe , Pr BRIGAND Cécile

Tous les auteurs :
Poterszman N, Baltzinger P, Mamulashvili Bessac D, Pham Van F, Goichot B, Mertz L, Addeo P, Brigand C, Imperiale A

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/40183957

Résumé

To address the efficacy and safety of [Lu]DOTATATE peptide receptor radionuclide therapy (PRRT) for peritoneal carcinomatosis/mesenteric fibrosis (PC/MF) with reference to liver metastases through sequential [Ga]DOTATOC PET/CT in patients with small-intestine neuroendocrine tumors (SiNETs).

Mots clés

Mesenteric fibrosis, Neuroendocrine, Peptide receptor radionuclide therapy, Peritoneal carcinomatosis, [177Lu]DOTATATE, [68Ga]DOTATOC

Référence

Eur J Nucl Med Mol Imaging. 2025 04 4;: